Page 5 - Simon Fox News Today

Frieze hinted it is willing to cooperate with the Galleries Association of Korea if it asks for help in expanding its presence overseas. Speaking at a press conference on Thursday at Coex in southern Seoul, Frieze CEO Simon Fox and Frieze Seoul’s director Patrick Lee said, “We would always be delighted to activate Frieze with Kiaf throughout the year.” In 2022, the London-based organizer and Seoul&r...

On September 7, 2023, Alnylam Pharmaceuticals announced positive topline data from the phase 2 KARDIA-1 trial of zilbesiran in the treatment of hypertension.

Art dealers question whether Frieze can sustain it's fairs in Seoul, Korea and New York at the same time.

Harp Nurseries has sold a fourth setting to Ashbourne Day Nurseries, which no longer has a director in common with the group.

A multipart, phase 1 trial provides evidence demonstrating the safety of zilbesarian, an RNA interference agent, which appeared to have a favorable safety profile among adult patients with hypertension.

— Dose-Dependent Reductions in Serum Angiotensinogen and 24-hour Ambulatory Blood Pressure Were Sustained for Six Months After Single Doses of Zilebesiran — — Acceptable Safety Profile Supporting Further Development —

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 19, 2023--

Plus: a Pistoletto sculpture has been destroyed in a suspected arson attack and Simon Lee Gallery has been placed under administration

London-based Frieze also purchased New York’s Armory Show, adding to its roster of art events.

Both fairs will continue to operate under their existing brands with their current teams.